274
Participants
Start Date
May 30, 2022
Primary Completion Date
April 16, 2027
Study Completion Date
April 16, 2027
S-531011
Administered by intravenous infusion
Pembrolizumab
Administered by intravenous infusion
RECRUITING
Fox Chase Cancer Center, Philadelphia
RECRUITING
University of Florida Health, Gainesville
RECRUITING
Henry Ford Health Center, Detroit
RECRUITING
MD Anderson Cancer Center, Houston
RECRUITING
Angeles Clinic and Research Center, Los Angeles
RECRUITING
National Cancer Center Hospital East, Kashiwa
RECRUITING
The University of Osaka Hospital, Suita
RECRUITING
National Cancer Center Hospital, Chuo Ku
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Shionogi
INDUSTRY